

Luminescent Re(I)/Au(I) Species As Selective Anticancer Agents for HeLa Cells

Andrés Luengo, Marta Redrado, Isabel Marzo, Vanesa Fernández-Moreira,* and M. Concepción Gimeno*



Cite This: <https://dx.doi.org/10.1021/acs.inorgchem.0c00813>



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: A series of neutral and cationic heterotrimetallic complexes of the type $fac-[Re(CO)_3(bipy(CC)_2)(AuL)_2X]^n$, where $bipy(CC)_2$ is 4,4'-alkynyl-2,2'-bipyridine; L is either triphenylphosphine (PPh_3), [1,3-bis(2,6-diisopropylphenyl)-imidazol-2-ylidene] (IPr), or *tert*-butyl isocyanide (CN^tBu); and X is a chloride ($n = 0$) or acetonitrile ($n = 1$), were synthesized and characterized together with their Re(I) precursors, i.e., $fac-[Re(CO)_3(bipy(CC)_2)X]^n$. X-ray diffraction of complexes 1, 3, and 6 corroborated the expected octahedral and linear distribution of the ligands along the Re(I) and Au(I) centers, respectively. Luminescent studies showed that all the complexes displayed a broad emission band centered between 565 and 680 nm, corresponding to a 3MLCT from the Re(I) to the diimine derivative. The presence of the gold fragment coordinated to the diimine ligand shifted in all cases the emission maxima toward higher energies. Such an emission difference could be potentially used for assessing the precise moment of interaction of the probe with the biological target if the gold fragment is implicated. Antiproliferative studies in cancer cells, A549 (lung cancer) and HeLa (cervix cancer), showed a generalized selectivity toward HeLa cells for those heterotrimetallic species incubated at longer times (72 vs 24 h). ICP-MS spectrometry revealed the greater cell internalization of cationic vs neutral species. Preliminary fluorescence microscopy experiments showed a different behavior of the complexes in HeLa and A549 cell lines. Whereas the complexes in A549 were randomly distributed in the outside of the cell, those incubated with HeLa cells were located close to the cellular membrane, suggesting some type of interaction, and possibly explaining their cellular selectivity when it comes to the antiproliferative activity displayed in the different cell lines.



INTRODUCTION

Molecular imaging is becoming one of the most important techniques within the development of novel treatments in medicine.¹ This technique involves a noninvasive study of the biological processes *in vivo* at a cellular level, rendering highly precise information. The key role would be the design of imaging agents that, combined with drugs, make them visible, quantifiable, and traceable over time. In this way, the development and optimization of specific treatments would be easier and more effective. Within this framework, the design of luminescent and bioactive heterometallic complexes offers a clear advantage over monometallic or organic molecules.² It can be hypothesized that the inherent properties of each metallic fragment are prone to be modulated separately. Later, when both fragments are combined, a synergistic effect would be expected to take place, possibly intensifying their therapeutic and traceability potential. In this particular regard, luminescent d^6 metal complexes combined with bioactive Au(I) or Ru(II) species, analogues to Auranofin or RAPTA, respectively,³ or just mimicking the coordination sphere of a specific drug, have been demonstrated to fulfill the require-

ment for becoming traceable luminescent and bioactive species, see Figure 1.⁴

In general, the use of luminescent d^6 metal complexes in cell imaging⁵ presents several advantages such as high photostability that renders high robustness to reach the biological targets intact. Additionally, they have long-lived phosphorescence that allows time-resolved detection, and their large Stokes shifts do not allow self-quenching mechanisms to take place. Both features improve the signal/noise ratio and as a consequence deliver greater image resolution. In the specific case of Re(I) complexes, the typical emissive structures are those derived from $fac-[Re(N^{\wedge}N)(CO)_3(L)]^{0/+}$, where $N^{\wedge}N$ represents a diimine ligand and L a halogen or a N-donor ligand. The emissive behavior is normally attributed to a metal-to-ligand-charge transfer (3MLCT) transition, where the

Received: March 17, 2020



ACS Publications

© XXXX American Chemical Society

A

<https://dx.doi.org/10.1021/acs.inorgchem.0c00813>
Inorg. Chem. XXXX, XXX, XXX–XXX




Figure 1. Examples of luminescent bioactive heterobimetallic species.^{3,4}

orbital of the diimine ligand is the main ligand contributor.⁶ In addition, in the recent years some rhenium tricarbonyl species have also showed antiproliferative potential in a wide range of tumor cancer cell lines,⁷ which could be used as a great input in the design of novel metallic drugs. Different combinations of Re(I)/Au(I) complexes have been described in the literature as promising candidates for trackable anticancer drugs. Figure 2 shows some examples of heterometallic *fac*-[Re(bipy)-




Figure 2. Examples of Re(I)/Au(I) species.^{8,9}

(CO)₃(L-AuPPh₃)⁺ complexes, where an imidazole derivative or an alkynyl-pyridine derivative was used as a linker between both metallic fragments.⁸ These heterobimetallic complexes were proven to bear good cytotoxicity against A549 lung cancer cells coming almost exclusively from the bioactive Au(I) fragment. Also some analogues derived from [(*fac*-[Re(bipy)(CO)₃(L)]₂Au)]³⁺ where L is a ditopic P,N-donor ligand have shown their suitability as trackable bioactive species. In all cases, the *fac*-{Re(bipy)(CO)₃} core was providing the traceability potential.⁹

In the search for the ultimate probe, it would be groundbreaking to be able to detect the precise moment of the interaction with the biological target. For doing so, a clear change of the emissive properties of the luminescent tag would be ideal. Such a change could be achieved if the interaction with the biological target directly affects the emissive orbitals of the luminescent tag. In the case of relying on Re(I) derivatives for the traceability, a wise approach would be to introduce the bioactive fragment within the diimine ligand, whose orbitals are the main ligand orbitals implicated in the emissive transition, i.e., ³MLCT. Therefore, it can be expected that once the complex reaches the biological target and the chemical transformation occurs between the bioactive fragment and the biological target, the emission would be clearly modified. The information obtained from this interaction could be used later to structurally refine the bioprobe in order to maximize the therapeutic potential. Thus, this work aims to

develop the first heterotrimetallic probes able to expose precisely the right time of reaching and/or interacting with the biological target.


RESULTS AND DISCUSSION

Synthesis and Characterization. Selected bioactive Au(I) fragments will be directly grafted onto the diimine ligand of species derived from *fac*-[Re(L_{NN})(CO)₃(L)]^{0/+} to allow detecting the precise moment of interaction of the probe with the biological target.

In this context, 4,4'-dialkynyl-2,2'-bipyridine (L_{NN}) was chosen as the linker ligand between both metal fragments. Thus, L_{NN} allows a direct electronic communication between both metals and any modification within the bioactive gold fragment, either disconnection from the luminescent tag (the Re(I) fragment) or replacement of the gold ancillary ligand for a biomolecule or any other residue will directly have a quantitative effect on the luminescence.

Starting from the 4,4'-dibromo-2,2'-bipyridine and following the same procedure described by Grosshenny and co-workers,¹⁰ L_{NN} was synthesized, see Scheme 1. After that,

Scheme 1. Schematic Synthetic Route for the Preparation of L_{NN} and the Rhenium and Gold Complexes 1–4^a




^a(i) TMSA, [Pd(PPh₃)₂Cl₂], CuI, DIPEA, THF; (ii) KF, MeOH; (iii) [Re(CO)₅Cl], toluene, 80 °C, 8 h; (iv) [Au(acac)(PPh₃)], DCM, rt, 3 h or [AuCl(IPr)], KOH, MeOH, rt, 24 h or [Au(CN^tBu)Cl], KOH, MeOH, rt, 1 night.

the Re(I) complex **1** was obtained by heating together stoichiometric amounts of L_{NN} and [Re(CO)₅Cl] in methanol. Subsequent additions of the different gold(I) substrates, either [Au(acac)(PPh₃)] in dichloromethane or the respective chloride gold derivatives of 1,3-bis(2,6-diisopropylphenyl)-imidazol-2-ylidene (IPr) and *tert*-buthylisocyanide CN^tBu in the presence of a base in methanol, delivered the expected neutral heterotrimetallic complexes **2–4** respectively, see Scheme 1.

At this point, the poor solubility of complexes **2–4** was already evident, which represents a serious drawback when it comes to test these species for biological applications. Therefore, the synthesis of the corresponding cationic

complexes was attempted by treatment of the chloride complexes 2–4 with silver triflate in acetonitrile, Scheme 2,

Scheme 2. Schematic Synthetic Procedure and Depiction of Final Complexes (5, 6, and 7)^a



^a(i) AgOTf, CH₃CN, 40 °C, 1 night; (ii) AgOTf, CH₃CN, 65 °C, 1 night; (iii) [Au(acac)(PPh₃)], CH₃CN, rt, 3 h; (iv) [Au(CN^tBu)Cl], KOH, MeOH, rt.

route A. In this way, the axial chloride ligand can be removed as insoluble AgCl and a molecule of solvent (CH₃CN) will be coordinated to the rhenium metal center instead. Despite several attempts with species 2–4, only in the case of complex 3 does the removal of the chloride and insertion of acetonitrile succeed, leading to the formation of complex 5. Conversely, the same reaction with complexes 2 and 4 afforded highly insoluble solids which could not be characterized. It is known that alkynyl gold complexes in the presence of a silver salt can afford highly insoluble polymers by coordination of the silver center to the alkynyl ligand and also establishing metallophilic interactions with the gold metals.¹¹ A similar explanation could be thought of in the present case. The lesser steric hindrance of PPh₃ and CN^tBu in comparison with that of the IPr ligand does not prevent the polymerization reaction to take place. Alternatively, a different strategy was considered for the preparation of the cationic compound derived from species 2 and 4, route B, Scheme 2. The abstraction of the chloride was performed on the rhenium precursor 1, rendering the cationic species 6. Then, coordination of the gold fragment was performed using the same conditions described before in Scheme 1 when complexes 2 and 4 were delivered, i.e., [Au(acac)(PPh₃)] and [Au(CN^tBu)Cl] as gold reactants, respectively. Unfortunately, only compound 7 was obtained. This time the handicap was the presence of a chloride ligand within the gold starting material, [Au(CN^tBu)Cl]. Complex 6 is highly sensitive to the presence of chloride ligands in the reaction media and compound 1 was obtained systematically, Scheme 2, route B.

Then, eventually, four neutral (species 1–4) and three cationic (5–7) metallic complexes were synthesized, five of them being heterotrimeric Re(I)/Au(I) species (2–5 and 7) and two monometallic Re(I) based (1 and 6). All of them, have been characterized by ¹H and ¹³C{¹H} NMR, FT-IR, and UV–vis spectroscopy as well as mass spectrometry, corroborating the accomplishment of their synthesis.

Additional ³¹P{¹H} NMR was performed for complexes 2 and 7. Analysis of the CO stretching frequencies ($\nu(\text{CO})$) of all the neutral complexes showed strong CO stretching bands around 2010–1885 cm^{−1}, which corroborate the expected carbonyl facial arrangements.¹² Alternatively, those bands for species 5–7 appear at higher frequency, around 2032 and 1917 cm^{−1}, indicative of the less effective π -backbonding between the CO and Re(I) center of cationic species. Moreover, heterometallic complexes lack $\nu(\text{H–CC})$ bands, which were observed for their rhenium precursors 1 and 6 at 3222 and 3202 cm^{−1}, respectively, indicating the success in the incorporation of the second metallic fragment. In all cases, ¹H NMR spectra were well-defined and showed the typical patterns for the bipyridine derivative coordinated to a *fac*-Re(CO)₃ core.¹³ Specifically, four set of peaks were observed in the aromatic area integrating for two protons each. In addition to these aromatic protons, also those belonging to the phenyl groups in complexes 2, 3, 5, and 7 appeared as multiplets. As expected, ¹³C{¹H} NMR spectra also showed clearly the presence of a gold metal fragment coordinated to the alkynyl carbon as the chemical shift for those C_{sp} atoms ranged from 99.5 to 110.2 ppm, whereas their Re(I) precursors 1 and 6 were at 87.3 and 79.9 ppm, respectively, see Table 1. Additionally, ³¹P{¹H} NMR

Table 1. Selected FTIR Stretching Bands (cm^{−1}), ¹³C{¹H} NMR and ³¹P{¹H} NMR (ppm) Chemical Shifts of 1–7

	$\nu(\text{C–O})$	$\nu(\text{H–CC})$	³¹ P{ ¹ H}	¹³ C{ ¹ H} (C ₇)
1	2016, 1884	3222		87.3
2	1998, 1884		41.5 ^a	110.2 ^a
3	2016, 1911, 1888			101.2 ^c
4	2016, 1887			99.5 ^d
5	2032, 1917			101.7 ^b
6	2034, 1917	3220		79.9 ^b
7	2029, 1905		41.0 ^b	100.8 ^b

^a¹³C{¹H} NMR and ³¹P{¹H} NMR were recorded in dichloromethane-d₂. ^b¹³C{¹H} NMR and ³¹P{¹H} NMR were recorded in acetonitrile-d₃. ^c¹³C{¹H} NMR and ³¹P{¹H} NMR were recorded in acetone-d₆. ^d¹³C{¹H} NMR and ³¹P{¹H} NMR were recorded in chloroform-d₁.

spectra of complexes 2 and 7 showed a single peak at 41.5 and 41.0 ppm, respectively, corresponding to each phosphorus atom coordinated to a different gold(I) fragment. Further analytical data provided by mass spectrometry corroborated the accomplishment of the synthesis.

X-ray Diffraction. Single crystals suitable for X-ray diffraction analysis of monometallic Re(I) complexes 1 and 6 were obtained by slow diffusion of pentane and ether into a solution of DCM or chloroform, respectively. In addition to them, the heterometallic complex 3 also gave suitable crystals for X-ray diffraction by slow diffusion of hexane into an acetone solution. Relevant crystallographic data are reported in Table S1.

Complex 1 crystallized in a monoclinic crystal system with a C2/c space group containing a Re(I) molecule together with a cocrystallized chloroform molecule within the asymmetric unit. As expected for these types of d⁶ metal complexes, the Re(I) coordination sphere can be described as a distorted octahedron, where the equatorial plane is formed by two carbonyl ligands and the bipyridine group. The third carbonyl together with the chloride ligand is placed in the apical axis. The source of the octahedral distortion is mainly due to the

constriction given by the chelated ligand, whose bite angle is 75.0(1) instead of 90° for an ideal octahedral geometry. The most relevant bond distances and angles are described in Figure 3, and all of them are within the range of values found




Figure 3. Povray view of one of the Re(I) molecules present in the asymmetric unit of complex 1 (left). Most relevant bond distances (Å) and angles (deg): Re(1)–C(1) 1.928(5), Re(1)–C(2) 1.923(6), Re(1)–C(3) 1.933(4), Re(1)–N(1) 2.170(4), Re(1)–N(2) 2.165(4), Re(1)–Cl(1) 2.477(4); N(1)–Re(1)–N(2) 75.0(1), N(1)–Re(1)–C(1) 176.4(1). Povray view of one of the Re(I) molecules present in the asymmetric unit of complex 6 (right). Most relevant bond distances (Å) and angles (deg): Re(1)–C(1) 1.917(4), Re(1)–C(2) 1.931(4), Re(1)–C(3) 1.923(4), Re(1)–N(1) 2.132(3), Re(1)–N(2) 2.161(3), Re(1)–N(3) 2.179(3); N(3)–Re(1)–N(2) 75.30(11), N(1)–Re(1)–C(1) 175.77(15). Triflate counterion has been removed for clarity.

for similar complexes.¹⁴ Complex 6 crystallized in a triclinic crystal system with a $P\bar{1}$ space group bearing two independent Re(I) molecules within the asymmetric unit as well as their corresponding triflate anion and a solvent pentane molecule. Once again, the Re(I) coordination sphere is described as distorted octahedron, following the same ligand distribution pattern seen for complex 1, except for the chloride ligand which now is substituted by an acetonitrile molecule bound to the metal center through the nitrogen atom (Figure 3 right and S1). Similarly, the octahedral distortion comes from the bite angle of the L_{NN} , close in both cases to 75°. The angles and bond distances for both Re(I) molecules within the asymmetric unit are very similar, being in both cases the longer Re–N and Re–C bond distances, these of the nitrogen belonged to the acetonitrile and carbon from the axial carbonyl ligand, respectively. The most relevant bond distances and angles are described in Figure 3 (right structure) and Figure S1.

Alternatively, the heterotrimetallic species 3 crystallized in an orthorhombic crystal system and in a $Pnma$ space group together with a molecule of acetone from the crystallization solvent mixture. The asymmetric unit is formed by half of a molecule, denoting the symmetry of the structure. As in previous examples, the rhenium metal center is disposed in an octahedral environment with a N–Re–N angle of 75.1(3)°. As expected, the gold atoms are coordinated in a linear fashion to the terminal alkynyl carbon and the carbene carbon with a C(1)–Au(1)–C(10) angle of 173.8(4). Relevant bond distances and angles can be seen in Figure 4. The chloride and a carbonyl ligands coordinated to rhenium atom in *trans* positions have been found to be disordered. They have been included in the model in two sets of positions, but only one is shown in the drawing and in the distances and angles below.




Figure 4. Povray view of complex 3. Most relevant bond distances (Å) and angles (deg): Re(1)–C(8) 1.912(9), Re(1)–C(9) 1.99(5), Re(1)–Cl(1) 2.408(7), Re(1)–N(1) 2.165(6); N(1)–Re(1)–N(1) 75.2(4), N(1)–Re(1)–C(8) 99.2(4), N(1)–Re(1)–C(9) 87.9(3), Cl(1)–Re(1)–C(9) 176.1(7); C(1)–Au(1) 1.998(9), C(10)–Au(1) 2.024(9); C(1)–Au(1)–C(10) 173.8(4).

Photophysical Studies. UV–vis absorption spectra were recorded for complexes 1–7 in a dimethyl sulfoxide solution at 298 K, see Table 2 and Figure S2. All of them showed a similar

Table 2. Absorption, Emission, Excitation Maxima of 1–7 in DMSO Solution at 298 K

complex	$\lambda_{\text{abs}}/\text{nm}$ ($10^4 \epsilon/\text{dm}^3 \times \text{mol}^{-1} \times \text{cm}^{-1}$)	$\lambda_{\text{em}}/\text{nm}$ ($\lambda_{\text{em}}/\text{nm}$)	τ/ns
1	261 (2.03), 308 (1.33), 333 (0.88), 398 (0.40)	680 (468)	12
2	276(4.23), 304(4.25), 340 (2.39), 395 (1.26)	651 (473)	80
3	272 (3.65), 310 (4.34), 343 (2.44), 385 (1.07)	635 (451)	
4	273 (3.66), 304 (4.99), 340(2.33), 390 (1.11)	663 (477)	44
5	272 (1.59), 289 (1.78), 306 (1.18), 345 (1.88)	565 (401)	
6	262 (2.93), 323 (1.42), 338 (1.51), 356 (0.67)	619 (437)	123
7	270 (3.31), 301 (3.33), 344 (2.17), 373 (1.15)	585 (421)	302

absorption profile that can be defined as a combination of ligand centered transitions (^1LC) at higher energies and a metal-to-ligand charge transfer transition ($^1\text{MLCT}$) at lower energies. Specifically, the absorption bands observed at approximately 270 nm and between 300 and 350 nm can be assigned to $\pi \rightarrow \pi^*$ (bipy, Ph) and $\pi \rightarrow \pi^*$ ($\text{C}\equiv\text{C}$) transitions, in concordance with similar alkynylbisimine Re(I) derivatives described in the literature.¹⁵ Additionally, the broad band close to 400 nm, with a tail up to 450 nm in some cases, is attributed to $\text{Re}(\text{d}\pi) \rightarrow \text{L}(\pi^*)$ transitions. The extended tail of this $^1\text{MLCT}$ band is probably due to the extended electronic delocalization among the alkynylbipyridine derivatives. In addition to the absorption measurements, emission measurements for all the species were analyzed in dimethyl sulfoxide at 298 K, Figure 5, and the most relevant data are collected in Table 2. Their emission patterns are alike, a broad emission band with the maxima between 565 and 680 nm, and the lifetime value ranges from 12 to 302 ns. As expected, cationic species have their maxima blue-shifted in comparison with their neutral counterparts¹⁶ due to the less electron density on




Figure 5. Normalized emission spectra for complexes 1–7 in dimethyl sulfoxide at 298 K.

the metal center that ultimately stabilizes the HOMO orbitals. In all cases the emission can be assigned to a $^3\text{MLCT}$ transition from the $d\pi(\text{Re}) \rightarrow \pi^*(\text{diimine})$, which has been previously reported in many rhenium(I) diimine tricarbonyl analogues.⁶ It is worth noticing that the heterotrimetallic analogues, both the neutral 2–4 and the cationic 5 and 7, presented their maxima at higher energies than their monometallic Re(I) precursors, complexes 1 and 6, respectively. Such behavior has been already seen for similar Re(I)/Au(I) species,^{15,17} and it can be explained based on the additional electron density that the gold fragment renders to the diimine. Higher electron donation into the diimine promotes the destabilization of the LUMO orbital, which is mainly centered in this ligand. Thus, the gold ancillary ligand nature and its ability to donate or withdraw electron density can be used to fine-tune the emission of the complexes, see Table 2.¹⁸ On the basis of these data, if there was a breakage or decoordination of the gold fragment or even substitution of the gold ancillary ligand when the interaction with the biological target takes place, fluorescence spectroscopy would allow detection of the precise moment of such an interaction, which was one of the requirements for the devised probes.

Antiproliferative Studies. The antiproliferative activity of complexes 1 to 7 was analyzed by MTT assay in the human lung cancer and breast cancer cell lines, A549 and HeLa, see Table 3. The experiments were performed at different incubation times, 24 and 72 h, as it is known that alkynyl gold derivatives need longer times to reveal their cytotoxicity in comparison to auranofin analogues (–SAuP–) or bisphosphines (PAuP) derivatives.¹⁹ The fact that the gold–carbon bond in alkynyl gold complexes is one of the strongest gold–ligand bonds²⁰ might be the driving force for delayed

Table 3. IC_{50} values (μM) of Complexes 1–7 Measured by MTT in A549 and HeLa Cells after 24 and 72 h Incubation

	A549-24 h	A549-72 h	HeLa-24 h	HeLa-72 h
1	>25	18.51 $\pm$ 3.71	17.01 $\pm$ 1.84	7.15 $\pm$ 0.47
2	>50	>25	>25	6.46 $\pm$ 0.35
3	>50	>25	>25	>25
4	>50	>25	>25	10.79 $\pm$ 0.48
5	>25	>25	>25	16.4 $\pm$ 2.80
6	8.37 $\pm$ 0.29	4.92 $\pm$ 0.38	5.10 $\pm$ 0.45	1.16 $\pm$ 0.13
7	>25	17.52 $\pm$ 1.40	18.8 $\pm$ 1.15	2.35 $\pm$ 0.06

time action. There is a clear difference between the antiproliferative activity of monometallic and heterometallic complexes, presenting the later higher cell selectivity toward HeLa cells at longer times. Moreover, greater cytotoxicity was seen for the cationic over neutral species. Specifically, the heterotrimetallic neutral complexes 2 and 4 showed selective antiproliferative activity after 72 h in the HeLa cell line, with IC_{50} values of 6.46 and 10.79 μM , respectively, whereas in the case of complex 3 the IC_{50} value was over 25 μM . On the contrary, the neutral Re(I) precursor, complex 1, already showed antiproliferative activity in A549 at 72 h as well as in HeLa cells at 24 h. The same trend has been shown by the cationic Re(I) complex 6, in this case with excellent IC_{50} values (<8 μM) probably because of its higher solubility. Regarding the cationic heterotrimetallic species, complexes 5 and 7, the selectivity toward inhibiting the proliferation of HeLa cells was not as evident as for their neutral analogue complexes 2–4, since complex 7 already showed a moderate cytotoxicity in A549 at 72 h and HeLa cells at 24 h (ca. 18 μM). However, it is clear that the mechanism of action of the heterotrimetallic probes involves somehow the gold fragment, which is what ultimately is providing the cell selectivity at longer times. Otherwise, the IC_{50} values of heterometallic complexes would be similar to those of their parent monometallic Re(I) complexes, where time dependence and cell selectivity were not clearly displayed. A closer look at the IC_{50} values also suggests that the gold ancillary ligands influence the cytotoxic behavior following the trend $-\text{PPh}_3 > -\text{CN}^t\text{Bu} > -\text{IPr}$, where the phosphine derivative is the most cytotoxic. Their role in the mechanism of action, or the way that they interfere within the internalization process of the probe might explain such behavior. Gold ancillary ligands are able to modulate the cellular uptake considerably due to their different lipo- or hydrophilic character, which is crucial for delivering the cytotoxic agent.²¹

In addition, the intracellular amount of Au(I) was analyzed by ICP-mass spectrometry for analogous neutral and cationic heterometallic complexes, species 2 and 7, respectively, in HeLa cells. The analyses showed that the cellular uptake of gold was double for 7 than that for 2, revealing the importance of the cationic nature for the internalization of the complexes, see Table 4. Moreover, it is worth mentioning that IC_{50} values

Table 4. Quantity of Gold (μM) Measured Inside HeLa Cells by ICP Mass Spectrometry after Incubation for 4 h

complex	$\mu\text{g gold}/10^5$ cells
2	1.420 $\pm$ 0.014
7	2.207 $\pm$ 0.017

are a combination of the intrinsic toxicity of the samples and their ability of internalization and solubility in biological media.²² Therefore, it seems clear that in this case, the ratio of toxicity for cationic to neutral complexes is higher than the ratio of uptake, corroborating that the intrinsic cytotoxicity of cationic species is greater than that of their neutral counterparts.

Fluorescence Microscopy. Cell distribution of complexes 1–7 was studied by fluorescence microscopy in A549 cells. In addition to them, either LysoTracker or MitoTracker were used as an internal standard to ascertain the localization pattern of the metallic species. Specifically, cell images were recorder after incubating 1–7 at 25 μM for 24 h in order to

not greatly increase the IC_{50} concentration. The irradiation wavelength used was thoroughly selected depending on their specific excitation and emissive properties, i.e., $\lambda_{exc} = 474$ nm, and collecting the emission between 490 and 590 nm for neutral and $\lambda_{exc} = 405$ nm and the emission window between 550 and 650 nm for cationic species.

In general, precipitation of the complexes was observed in the extracellular region, which prevailed over accumulation inside the cell, particularly evident for those complexes of a neutral nature, 1–4, incubated at a high concentration in A549. Figure 6 showed an example of the extracellular precipitate of complexes 1 and 2.




Figure 6. Images of 1 (top row) and 2 (bottom row) after incubation with A549 (24 h) and LysoTracker Red-DND99 (30 min). (A) Image after irradiation at 473; (B) after irradiation at 588 nm; (C) superimposition picture of A and B; (D) superimposition with bright field image. Green, complexes 1 and 2; red, internal standard.

Moreover, a comparison between the images recorded for complexes 1 and 2 (Figure 6) and for complexes 3 and 4 (Figure S3), the four of them incubated with A549 cells under the same conditions, clearly showed the lower solubility properties of species 3 and 4. Therefore, it can be suggested that the gold ancillary ligands of complexes 3 and 4, i.e., IPr and CN^tBu , greatly contributed to the low solubility of the compounds. The cationic species 5 and 7 followed a similar trend as their neutral counterparts when incubated with A549 cells, and only the precipitated complex was clearly seen in the surroundings of the cells, see Figure S4. Alternatively, the monometallic rhenium complex 6 incubated in A549 at $25 \mu M$ led directly to cell death, see Figure 7, corroborating the low IC_{50} value of $8.37 \pm 0.29 \mu M$ found for this particular species.

In addition to the analysis of the distribution of complexes 1–7 in A549 cells, further fluorescence microscopy studies were performed in HeLa cells to evaluate the higher antiproliferative activity displayed in this cell line. Thus, complexes 1–7 were incubated with HeLa cells for 24 h, this time at $5 \mu M$ in order to prevent a high percentage of cell death. Analogous to the previous image assay, a considerable amount of precipitate was observed in the outer cell membrane media for the heterotrimetallic species. The main difference with the previous experiment (see Figure 6 and S3) is that most of the precipitate is located very close to the cell membrane, see Figures 8 and S5. Therefore, it seems plausible to think that an interaction with the membrane of HeLa cells could be taking place. Despite that, none of the species could be seen inside the cell, and elucidation of their inner distribution or interaction could not be made. The fact that no heterotrimetallic complex was seen inside the cell could be




Figure 7. Complex 6 incubated with A549 at $25 \mu M$ for 24 h.




Figure 8. Images of 2 (top row) and 4 (bottom row) after incubation with HeLa (24 h) at $5 \mu M$ and MitoTracker Red (15 min). Red emission: MitoTracker. Green emission of complexes 2 and 4. (A) Emission of the complex 2; (B) superimposition with bright field. (C) Emission of the complex 4 and MitoTracker; (D) superimposition with bright field image.

due to either poor cell permeability, low emission efficiency, or even emission quenching processes.

In a final attempt to shed a bit of light on the different antiproliferative characters of the heterotrimetallic complexes in HeLa cells in comparison with A549, a different experiment was performed. This time the complexes were incubated with HeLa cells at $25 \mu M$ while reducing the incubation time to 4 h in order not to disrupt the cell viability. The experiment was only performed for the cationic species (5–7) due to the low solubility displayed for the neutral species in the previous assays as well as their lower internalization found by ICP-mass spectrometry. Thus, monometallic Re(I) complex 6 revealed the cell immersed in a cell death process, which corroborates the high cytotoxicity observed for this complex in HeLa cells at

only 24 h of incubation ($5.10 \pm 0.45 \mu\text{M}$), see Figure 9. No solid was observed outside the cell, suggesting that the complex has been internalized.




Figure 9. Images of **6** after incubation with HeLa (4 h) at $25 \mu\text{M}$.

Following the same trend as before, when incubated at $5 \mu\text{M}$, cationic species **5** and **7** got stuck and/or adhered to the outer part of the cell membrane, see Figure 10. Such a




Figure 10. Images of **5** (top row) and **7** (bottom row) after incubation with HeLa (4 h) at $25 \mu\text{M}$ and MitoTracker Red (15 min). Red emission: MitoTracker. Green emission of complexes **5** and **7**. (A) Emission of the complex **5** and MitoTracker; (B) superimposition with bright field. (C) Emission of the complex **7** and MitoTracker; (D) superimposition with bright field image at $25 \mu\text{M}$ for 4 h.

localization pattern on HeLa cells, completely different from that seen in A549 cells, where the solid was randomly distributed through the outer cell media (Figure S4), might be the key for the higher selectivity and cytotoxicity seen toward the HeLa cell line. In addition, it is worth noticing that the presence of the gold fragment is somehow implicated in such a

localization pattern, since the monometallic Re(I) species complex **6** behaves completely differently and no solid is distributed within the surroundings of the cell, Figure 9 vs Figure 10. Therefore, it can be concluded that the mechanisms of action of monometallic rhenium and trimetallic rhenium/gold derivatives differ from each other. Moreover, it is feasible to think that the gold fragment is the driving force toward the cell selective cytotoxicity and that differences in the membrane composition of HeLa and A549 cells might be encouraging such differentiation. In fact, cancer cells present lipid alterations in their cell membrane.²³ Studies have shown variations of phospholipid-to-protein, cholesterol-to-protein, and cholesterol-to-phospholipid ratios, as well as in the fatty acid composition of the phospholipids of different cancer cell line membranes,²⁴ which in this case must be critical for the cell specificity of our heterometallic probes.

EXPERIMENTAL SECTION

General Measurements and Analysis Instrumentation. Mass spectra were recorded on a Bruker Esquire 3000 Plus, with the electrospray (ESI) technique, and on a Bruker MALDI-TOF device. ^1H , $^{13}\text{C}\{^1\text{H}\}$, and $^{31}\text{P}\{^1\text{H}\}$ NMR, including 2D experiments, were recorded at room temperature on a Bruker Avance 400 spectrometer (^1H , 400 MHz, ^{13}C , 100.6 MHz, ^{31}P , 162 MHz) with chemical shifts (δ , ppm) reported relative to the solvent peaks of the deuterated solvent. Infrared spectra were recorded in the range $4000\text{--}250 \text{ cm}^{-1}$ on a PerkinElmer Spectrum 100 FTIR spectrometer. Room temperature steady-state emission and excitation spectra were recorded with a Jobin-Yvon-Horiba fluorolog FL3-11 spectrometer fitted with a JY TBX picosecond detection module. Nanosecond lifetimes were recorded with a DataStation HUB-B with a nanoLED controller and DAS6 software. The nanoLEDs employed for lifetime measurements were of 370 and 390 nm. The lifetime data were fitted using the Jobin-Yvon software package and the Origin Pro 8 program. UV-vis spectra were recorded with 1 cm quartz cells on an Evolution 600 spectrophotometer. The quantum yields were measured in a 300–950 nm Hamamatsu Photonics Quantaaurus-QY.

Crystal Structure Determinations. Crystals were mounted in inert oil on glass fibers and transferred to the cold gas stream of an Xcalibur Oxford Diffraction diffractometer or Bruker Apex Duo equipped with low-temperature attachments. Data were collected using monochromated Mo $K\alpha$ radiation ($\lambda = 0.71073 \text{ \AA}$). The scan type was ω . Absorption correction based on multiple scans was applied using spherical harmonics implemented in the SCALE3 ABSPACK scaling algorithm²⁵ or with SADABS. The structures were solved by direct methods and refined on F^2 using the program SHELXL-2016.²⁶

Antiproliferative Studies: MTT Assay. Exponentially growing cells (A549 or HeLa) were seeded at a density of approximately 10^4 cells per well in 96-well flat-bottomed microplates and allowed to attach for 24 h prior to the addition of compounds. The complexes were dissolved in DMSO and added to cells in concentrations ranging from 50 to $0.5 \mu\text{M}$ or by 25 to $0.5 \mu\text{M}$, in quadruplicate. Cells were incubated with our compounds for 24 or 72 h at 37°C . Ten microliters of MTT (5 mg mL^{-1}) was added to each well, and plates were incubated for 2 h at 37°C . Finally, the growth medium was eliminated, and DMSO ($100 \mu\text{L}$ per well) was added to dissolve the formazan precipitates. The optical density was measured at 550 nm using a 96-well multiscanner autoreader (ELISA). The IC_{50} was calculated by nonlinear regression analysis.

ICP-Mass. Twelve-well plates were seeded with 10^5 cells (HeLa/A549) in 1.6 mL of culture medium per well. Cultures were incubated at 37°C in an atmosphere of 5% $\text{CO}_2/95\%$ for 24 h. The culture medium was then removed and replaced with 2 mL of drug containing medium at $25 \mu\text{M}$. After 4 h of incubation at 37°C , the medium was removed and the cell monolayer washed two times with phosphate-buffer saline. Then, 1 mL of a trypsin solution was added, and the plate was placed in the incubator for 5 min. A total of $500 \mu\text{L}$

of fresh medium was then added, and the resulting suspension was pelleted in a 1.5 mL eppendorf by centrifuging for 5 min at 1200 rpm. The pellets were resuspended in 500 μ L of fresh medium, and a 50 μ L fraction was separated for cell counting after staining with Trypan Blue. The suspension was centrifuged again. The medium was removed, and 0.5 mL of concentrated aqua regia was added for digestion overnight. The resulting solutions were diluted gravimetrically with ultrapure water and analyzed by ICP-MS. Measurements were performed by an ICP quadrupole mass spectrometer (Elan DRC-e, PerkinElmer, Shelton, CT, USA) equipped with a standard ICP torch, cross-flow nebulizer, nickel sampler, and skimmer cones and DRC. PTFE vessels, micropipette tips, eppendorfs for digestion, and polypropylene (PP) tubes were cleaned in 10% HNO₃ overnight and rinsed thoroughly with ultrapure water.

Cell Fluorescence Microscopy Study. The European Collection of Cell Cultures was maintained in HEPES modified minimum essential medium (DMEM) supplemented with 5% fetal bovine serum, penicillin, and streptomycin. A549 cells were detached from the plastic flask using trypsin-EDTA solution and suspended in an excess volume of growth medium. A total of 300 μ L of a homogeneous cell suspension was then distributed into an μ -slide 8 well ibiTreat; the cells were allowed to attach for 24 h prior to the addition of compounds. Then, 200 μ L of culture medium was removed, and 100 μ L of a solution of the corresponding complexes was added to the cells up to a final concentration of 5 or 25 μ M. The complexes were incubated with the cells for 4 or 24 h at 37 °C, depending on the experiment. Thereafter, 50 μ L of MitoTracker Red or LysoTracker Red DND-99 was added up to a final concentration of 10 nM. They were incubated with the cells for 15 min (MitoTracker) or 30 min (LysoTracker) at room temperature. Eventually, the medium was replaced with fresh medium without phenol red. Preparations were viewed using an Olympus FV10-i Oil type compact confocal laser microscope using a $\times$ 10 or $\times$ 60 objective, with excitation wavelengths at 405, 473, and 588 nm.

Materials and Procedures. The starting material [Au(acac)-(PPh₃)],²⁷ [Au(CN'Bu)Cl],²⁸ [AuCl(PPh₃)],²⁹ and [AuClIPr]³⁰ were prepared according to literature procedures, and their experimental data agree with those reported.^{27–30} All other starting materials and solvents were purchased from commercial suppliers and used as received unless otherwise stated.

Synthesis of Complex 1. 4,4'-Alkynyl-2,2'-bipyridine (L_{NN}; 129 mg, 0.632 mmol) and [Re(CO)₅Cl] (228.7 mg, 0.632 mmol) were suspended in toluene (10 mL) and heated at 80 °C for 8 h. The suspension was cooled to room temperature, and the solid was filtered and then washed with a small amount of toluene and petroleum ether. The compound was obtained as an orange solid (306.3 mg, 95%). ¹H NMR (400 MHz, CDCl₃): δ 9.01 (d, J = 5.8 Hz, 2H, H₆), 8.20 (sbr, 2H, H₃), 7.55 (dd, J = 5.8, 1.7 Hz, 2H, H₅), 3.65 (s, 2H, H₈). ¹³C NMR (101 MHz, CDCl₃): δ 196.9 (s, CO), 190.3 (s, CO), 155.3 (s, 2C, C₆), 153.2 (s, 2C, C₂), 133.9 (s, 2C, C₄), 129.6 (s, 2C, C₃), 128.3 (s, 2C, C₈), 125.7 (s, 2C, C₅), 87.3 (s, 2C, C₇). IR (ν , cm⁻¹): 3222 (C $\equiv$ C–H), 3056 (C_{Ar}–H), 2107 (C $\equiv$ C), 2016, 1884 (CO), 1605 (C_{Ar}=N). HRMS (m/z): 532.9685 [M – Cl + Na], C₁₇H₈ClN₂NaClO₃Re (532.9664).

Synthesis of Complex 2. To a stirred solution of complex 1 (13 mg, 0.0255 mmol) in DCM (2.5 mL) was added [Au(acac)(PPh₃)] (28.2 mg, 0.051 mmol). After 3 h of stirring at room temperature, the solvent was reduced to minimum volume, and petroleum ether was added to afford a yellow solid (yield 28.6 mg, 79%). ¹H NMR (300 MHz, CD₂Cl₂): δ 8.78 (d, J = 5.8 Hz, 2H, H₆), 8.10 (d, J = 1.7 Hz, 2H, H₃), 7.63–7.45 (m, 30H, H_{Ar}, Ph), 7.41 (dd, J = 5.8, 1.6 Hz, 2H, H₅). ¹³C NMR (75 MHz, CD₂Cl₂): δ 198.47 (s, CO), 155.85 (s, 2C, C₂), 152.76 (s, 2C, C₆), 137.62 (s, 2C, C₄), 134.86 (d, ² J_{P-C} = 13.8 Hz, 12C, *o*-C, Ph), 132.38 (s, 12C, *p*-C, Ph), 129.99 (d, ¹ J_{P-C} = 57.3 Hz, 6C, *i*-C, Ph), 129.86 (d, ² J_{P-C} = 11.3 Hz, 12C, *m*-C, Ph), 129.86 (s, 2C, C₅), 126.37 (s, 2C, C₃), 110.60 (s, 1C, C₈), 100.22 (s, 1C, C₇). ³¹P NMR (121 MHz, CD₂Cl₂): δ 41.5 (s). IR (ν , cm⁻¹): 3046 (C_{Ar}–H), 2107 (C $\equiv$ C), 1998, 1884 (CO), 1600 (C_{Ar}=N). MALDI-HRMS (m/z): 1391.1089 [M–Cl], C₅₃H₃₆Au₂N₂O₃P₂Re (1391.1090).

Synthesis of Complex 3. To a stirred solution of complex 1 (15 mg, 0.0294 mmol) and [AuClIPr] (36.6 mg, 0.589 mmol) in MeOH (5 mL) was added a solution of KOH (3.87 mg, 0.0588 mmol) in MeOH (3 mL). The mixture was stirred 24 h at room temperature and then purified by alumina column chromatography employing ether/MeOH (97:3 to 93:7). The product was obtained as a yellow solid (yield 22.4 mg, 45%). ¹H NMR (300 MHz, acetone-*d*₆): δ 8.67 (d_{br}, J = 5.8 Hz, 2H, H₆), 8.22 (d_{br}, J = 1.6 Hz, 2H, H₃), 7.81 (s, 4H, H₁₀), 7.61 (t, J = 7.8 Hz, 4H, H₁₄), 7.45 (d, J = 7.8 Hz, 8H, H₁₃), 7.24 (dd, J = 5.8, 1.6 Hz, 2H, H₅), 2.72 (t, J = 6.9 Hz, 4H, H₁₅), 2.68 (t, J = 6.9 Hz, 4H, H₁₅), 1.39 (d, J = 6.9 Hz, 24H, CH₃), 1.27 (d, J = 6.9 Hz, 24H, CH₃). ¹³C NMR (101 MHz, acetone-*d*₆): δ 199.26 (s, CO), 191.08 (s, CO), 189.94 (s, 2C, C₉), 156.34 (s, 2C, C₂), 152.64 (s, 2C, C₆), 148.63 (s, 2C, C₈), 146.68 (s, 4C, C₁₂), 139.06 (s, 2C, C₄), 135.40 (s, 4C, C₁₁), 131.41 (s, 2C, C₁₄), 129.78 (s, 2C, C₅), 126.91 (s, 2C, C₃), 125.32 (s, 4C, C₁₀), 125.00 (s, 8C, C₁₃), 101.18 (s, 2C, C₇), 24.91 (s, 8C, CH₃), 24.13 (s, 8C, CH₃). IR (ν , cm⁻¹): 2111 (C $\equiv$ C), 2016, 1911, 1888 (CO), 1603 (C_{Ar}=N).

Synthesis of Complex 4. To a suspension of complex 1 (40 mg, 0.078 mmol) and *tert*-butylisocyanide gold chloride (49.5 mg, 0.157 mmol) in MeOH (5 mL) was added a solution of KOH (10.3 mg, 0.157 mmol) in MeOH (1 mL), and the mixture was allowed to react for 12 h at room temperature. The solvent was then evaporated and the residue dissolved in DCM. After filtration over Celite, the volume was reduced to 1–2 mL, and ether was added to precipitate complex 4 as a yellow solid (yield 64.5 mg, 77%). ¹H NMR (400 MHz, CDCl₃): δ 8.81 (d, J = 5.8 Hz, 2H, H₂), 8.04 (d, J = 1.6 Hz, 2H, H₃), 7.38 (dd, J = 5.8, 1.6 Hz, 2H, H₃), 1.60 (s, 18H, H₁₁). ¹³C NMR (101 MHz, CDCl₃): δ 197.52 (s, CO), 189.91 (s, CO), 155.37 (s, 2C, C₆), 152.40 (s, 2C, C₂), 137.34 (s, 2C, C₉), 136.73 (s, 2C, C₄), 129.58 (s, 2C, C₃), 126.07 (s, 2C, C₅), 99.50 (s, 2C, C₇), 59.12 (s, 2C, C₁₀), 29.94 (s, 6C, C₁₁). IR (cm⁻¹): ν 2984 (C_{sp}³–H), ν 2231 (C $\equiv$ N), ν 2119 (C $\equiv$ C), ν 2016, 1887 (CO), ν 1603 (C_{Ar}=N).

Synthesis of Complex 5. To a stirred solution of 1 (1 equiv, 22.6 mg, 0.013 mmol) in acetonitrile (5 mL) was added AgOTf (1.1 equiv, 3.7 mg, 0.014 mmol), and the reaction mixture was allowed to react at 40 °C overnight. The suspension was then filtrated over Celite, and the solvent was evaporated. The crude was washed with ether three times to afford an orange solid corresponding to 5 (18.4 mg, 75%). ¹H NMR (400 MHz, CD₃CN): δ 8.64 (d, J = 5.8 Hz, 2H, H₆), 8.11 (d, J = 1.6 Hz, 2H, H₃), 7.64 (t, J = 7.8 Hz, 4H, H₁₄), 7.54 (s, 4H, H₁₀), 7.46 (d, J = 7.8 Hz, 8H, H₁₃), 7.28 (dd, J = 5.8, 1.6 Hz, 2H, H₅), 2.62 (quint, J = 6.9 Hz, 8H, H₁₅), 2.13 (s, 3H, H₁₉), 1.37 (s, 12H, CH₃-IPr), 1.36 (s, 12H, CH₃-IPr), 1.29 (s, 12H, CH₃-IPr), 1.28 (s, 12H, CH₃-IPr). ¹³C NMR (101 MHz, CD₃CN): δ 189.34 (s, 2C, C₉), 156.58 (s, 2C, C₂), 153.84 (s, 2C, C₆), 148.49 (s, C₈), 147.01 (s, 8C, C₁₂), 139.47 (s, 2C, C₄), 135.17 (s, 4C, C₁₁), 131.66 (s, 4C, C₁₄), 130.47 (s, 2C, C₅), 127.54 (s, 2C, C₃), 125.28 (s, 4C, C₁₀), 125.17 (s, 8C, C₁₃), 101.68 (s, 2C, C₇), 29.63 (s, 8C, C₁₅), 24.82 (s, 8C, CH₃-IPr), 23.99 (s, 8C, CH₃-IPr). IR (cm⁻¹): ν 2961 (C_{sp}³–H), ν 2107 (C $\equiv$ C), ν 2032, 1917 (CO), ν 1602 (C_{Ar}=N). MALDI: 1643.4. Calcd M-NCCH₃: 1643.5

Synthesis of Complex 6. To a stirred solution of 1 (1 eq, 50 mg, 0.098 mmol) in acetonitrile (5 mL) was added AgOTf (1.1 eq, 27.8 mg, 0.108 mmol), and the reaction mixture was allowed to react overnight. The suspension was then filtrated over Celite and concentrated, and ether was added to precipitate a yellow solid corresponding to 6 (49.6 mg, 76%). ¹H NMR (400 MHz, CD₃CN): δ 8.98 (dd, J = 5.8, 0.6 Hz, 1H, H₆), 8.58 (d, J = 1.1 Hz, 1H, H₃), 7.74 (dd, J = 5.8, 1.6 Hz, 1H, H₅), 4.16 (s, 1H, H₈), 2.05 (s, 3H, H₁₀). ¹³C NMR (101 MHz, CD₃CN): δ 156.93 (s, C₂), 155.13 (s, C₆), 135.75 (s, C₄), 131.28 (s, C₅), 128.14 (s, C₃), 123.68 (s, C₉), 89.28 (s, C₈), 79.94 (s, C₇), 3.99 (s, C₁₀). IR (cm⁻¹): ν 3202 (C_{sp}³–H), ν 2104 (C $\equiv$ C), ν 2034, 1917 (CO), ν 1609 (C_{Ar}=N). HRMS (m/z): 516.0341 M⁺, C₁₉H₁₁N₃O₃Re (516.0353)

Synthesis of Complex 7. To a stirred solution of 6 (1 equiv, 20 mg, 0.03 mmol) in acetonitrile (5 mL) was added [Au(acac)PPh₃] (2 equiv, 33.6 mg, 0.06 mmol) with a change in the color of the solution from yellow to brown. After 3 h of reaction, the solution was filtrated over Celite and concentrated, and ether was added to precipitate a

light brown solid corresponding to 7 (39.3 mg, 83%). ^1H NMR (300 MHz, CD_3CN): δ 8.80 (d, J = 5.8 Hz, 2H, H_6), 8.40 (s, 2H, H_3), 7.65–7.50 (m, 16H, H_{Ar} + H_5), 2.06 (s, 3H, H_{10}). ^{13}C NMR (75 MHz, CD_3CN): δ 194.98 (s, CO), 191.73 (s, CO), 156.88 (s, 2C, C_2), 154.12 (s, 2C, C_6), 138.81 (s, 2C, C_4), 135.19 (s, 12C, o-C, Ph), 133.08 (s, 6C, p-C, Ph), 130.86 (s, 2C, C_3), 130.57 (s, 12C, m-C, Ph), 127.69 (s, 2C, C_3), 123.31 (s, C_9), 100.82 (s, 2C, C_7), 4.14 (s, C_{10}). ^{31}P NMR (121 MHz, CD_3CN): δ 40.88 (s). IR (cm^{-1}): ν 3053 ($\text{C}_{\text{sp}^2}\text{--H}$), ν 2108 ($\text{C}\equiv\text{C}$), ν 2029, 1905 (CO), ν 1600 ($\text{C}_{\text{Ar}}=\text{N}$). MALDI: 1391.0. Calcd: M--NCCH_3 , 1391.1

CONCLUSIONS

In the search for a new family of metallic-based luminescent anticancer agents that allow detection of the precise moment of interaction with the biological target, three neutral and two cationic heterotrimetallic $\text{Re(I)}/\text{Au(I)}$ complexes were synthesized together with their monometallic Re(I) precursors. A key ligand, 4,4'-dialkynyl-2,2'-bipyridine (L_{NN}), was used as a linker between the two types of metals, coordinating the rhenium atom through the nitrogen atoms in a bidentate mode and the gold atoms through the terminal alkynyl carbons. Either triphenylphosphine (PPh_3), 1,3-bis(2,6-diisopropylphenyl)-imidazol-2-ylidene (IPr), or *tert*-butyl isocyanide (CN^tBu) was used as a gold ancillary ligand in order to modulate the luminescent and/or bioactivity of the probes. As expected, all of them are emissive in the range of 565–680 nm, and the emission, mostly due to the Re(I) fragment, was assigned to a $^3\text{MLCT}$ transition from the $d\pi(\text{Re}) \rightarrow \pi^*(\text{L}_{\text{NN}})$. In addition, heterometallic species displayed a blue-shifted emission in comparison with that of their monometallic Re(I) counterparts. This fact could be ultimately used to monitor an interaction between 2 and 5 or 7 with a biological target, if such interaction promotes the release of the gold fragment. Crystal structures were obtained for species 1, 3, and 6, showing the expected *facial* disposition of the tricarbonyl ligands and confirming the bidentate character of the L_{NN} as well as the linearity of the gold coordination mode. An antiproliferative assay in A549 (lung cancer) and HeLa (cervix cancer) cells revealed three important features: first, the improvement in the cytotoxicity values of the cationic species in comparison with their neutral equivalents; second, the enhancement of the toxicity over time; and finally, the general selectivity of the heterotrimetallic species toward HeLa cells with the exception of complex 3. ICP-mass spectrometry corroborated the greater cell internalization of the heterometallic cationic species. Fluorescence microscopy assays were performed to elucidate their distribution pattern and the different cytotoxic behavior in both cell lines, A549 and HeLa. The low solubility, especially that of neutral complexes, was evident using this technique, as lot of solid was randomly seen in the outside of the cells when incubated with A549. On the contrary, for the heterotrimetallic species in HeLa cells, the distribution of the complexes changed. In this case, the solid was located very close, and possibly interacting with the outer cellular membrane, which might be triggering the selectivity and higher toxicity toward the HeLa cell line over A549. Such behavior was not observed for the monometallic Re(I) complexes, suggesting a different mechanism of action. Therefore, the higher selectivity for HeLa over A549 cells displayed by heterometallic species can be associated with the gold fragment, which somehow is the main responsibility. Possibly a different composition of HeLa and A549 cell membranes makes possible such differentiation, causing the heterotrimetallic species to be more sensitive toward HeLa cell

membranes. Future heterometallic probes, as in general any species designed to become drugs, should consider solubility in biological environments and targeting as one of their main features to retain. For that, alternatives such as introducing water-soluble groups or, even better, amino acid or small peptides could deliver great advantages embracing solubility and specific targeting.³¹

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.inorgchem.0c00813>.

Additional figures and tables and crystallographic data (PDF)

Accession Codes

CCDC 1973254–1973256 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

AUTHOR INFORMATION

Corresponding Authors

Vanesa Fernández-Moreira – Departamento de Química Inorgánica, Instituto de Síntesis Química y Catálisis Homogénea (ISQCH) CSIC-Universidad de Zaragoza, 50009 Zaragoza, Spain; orcid.org/0000-0002-1218-7218; Email: vanesa@unizar.es

M. Concepción Gimeno – Departamento de Química Inorgánica, Instituto de Síntesis Química y Catálisis Homogénea (ISQCH) CSIC-Universidad de Zaragoza, 50009 Zaragoza, Spain; orcid.org/0000-0003-0553-0695; Email: gimeno@unizar.es

Authors

Andrés Luengo – Departamento de Química Inorgánica, Instituto de Síntesis Química y Catálisis Homogénea (ISQCH) CSIC-Universidad de Zaragoza, 50009 Zaragoza, Spain

Marta Redrado – Departamento de Química Inorgánica, Instituto de Síntesis Química y Catálisis Homogénea (ISQCH) CSIC-Universidad de Zaragoza, 50009 Zaragoza, Spain

Isabel Marzo – Departamento de Bioquímica y Biología Molecular, Universidad de Zaragoza, 50009 Zaragoza, Spain

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.inorgchem.0c00813>

Author Contributions

All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors thank the Ministerio de Economía y Competitividad (MINECO-FEDER CTQ2016-75816-C2-1-P), the Ministerio de Ciencia Innovación y Universidades (RTI2018-097836-J-I00 and RED2018-102471-T), and Gobierno de Aragón-Fondo Social Europeo (E07_20R) for financial support. A.L. and M.R. thank the Gobierno de Aragón for a predoctoral fellowship. We are grateful to Pilar García-Orduña for her help with the refinement of the X-ray structures.

REFERENCES

- (1) Chen, K.; Chen, X. Design and development of molecular imaging probes. *Curr. Top. Med. Chem.* **2010**, *10*, 1227–1236.
- (2) Fernández-Moreira, V.; Gimeno, M. C. Heterobimetallic complexes for theranostic applications. *Chem. - Eur. J.* **2018**, *24*, 3345–3353.
- (3) Wenzel, M.; de Almeida, A.; Bigaeva, E.; Kavanagh, P.; Picquet, M.; Le Gendre, P.; Bodio, E.; Casini, A. New Luminescent Polynuclear Metal Complexes with Anticancer Properties: Toward Structure–Activity Relationships. *Inorg. Chem.* **2016**, *55*, 2544–2557.
- (4) Boselli, L.; Carraz, M.; Mazères, S.; Paloque, L.; González, G.; Benoit-Vical, F.; Valentin, A.; Hemmert, C.; Gornitzka, H. Synthesis, structures, and biological studies of heterobimetallic Au(I)–Ru(II) complexes involving N-heterocyclic carbene-based multidentate ligands. *Organometallics* **2015**, *34*, 1046–1055.
- (5) (a) Fernández-Moreira, V.; Thorp-Greenwood, F. L.; Coogan, M. P. Application of d⁶ transition metal complexes in fluorescence cell imaging. *Chem. Commun.* **2010**, *46*, 186–202. (b) Lee, L. C.-C.; Leung, K.-K.; Lo, K. K.-W. Recent development of luminescent rhenium(I) tricarbonyl polypyridine complexes as cellular imaging reagents, anticancer drugs, and antibacterial agents. *Dalton Trans.* **2017**, *46*, 16357–16380.
- (6) Kumar, A.; Sun, S.-S.; Lees, A. J. Photophysics and photochemistry of organometallic rhenium diimine complexes. *Photophysics of Organometallics* **2009**, *29*, 37–71.
- (7) (a) Konkankit, C. C.; King, A. P.; Knopf, K. M.; Southard, T. L.; Wilson, J. J. In Vivo Anticancer Activity of a Rhenium(I) Tricarbonyl Complex. *ACS Med. Chem. Lett.* **2019**, *10*, 822–827. (b) Knopf, K. M.; Murphy, B. L.; MacMillan, S. N.; Baskin, J. M.; Barr, M. P.; Boros, E.; Wilson, J. J. In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes. *J. Am. Chem. Soc.* **2017**, *139*, 14302–14314. (c) Redshaw, C.; Watkins, S.; Humphrey, S. M.; Bulman Page, P. C.; Ashby, S.; Chao, Y.; Herbert, C. J.; Mueller, A. Rhenium(I) phenanthrolines bearing electron withdrawing CF₃ substituents: synthesis, characterization and biological evaluation. *RSC Adv.* **2013**, *3*, 23963–23966.
- (8) Fernández-Moreira, V.; Marzo, I.; Gimeno, M. C. Luminescent Re(I) and Re(I)/Au(I) complexes as cooperative partners in cell imaging and cancer therapy. *Chem. Sci.* **2014**, *5*, 4434–4446.
- (9) Luengo, A.; Fernández-Moreira, V.; Marzo, I.; Gimeno, M. C. Trackable Metallodrugs Combining Luminescent Re(I) and Bioactive Au(I) Fragments. *Inorg. Chem.* **2017**, *56*, 15159–15170.
- (10) Grosshenny, V.; Romero, F. M.; Ziesse, R. Construction of preorganized polytopic ligands via palladium-promoted cross-coupling reactions. *J. Org. Chem.* **1997**, *62*, 1491–1500.
- (11) (a) Blanco, M. C.; Cámara, J.; Gimeno, M. C.; Laguna, A.; James, S. L.; Lagunas, M. C.; Villacampa, M. D. Synthesis of Gold–Silver Luminescent Honeycomb Aggregates by Both Solvent-Based and Solvent-Free Methods. *Angew. Chem., Int. Ed.* **2012**, *51*, 9777–9779. (b) Blanco, M. C.; Cámara, J.; Gimeno, M. C.; Jones, P. G.; Laguna, A.; López-de-Luzuriaga, J. M.; Olmos, M. E.; Villacampa, M. D. Luminescent Homo- and Heteropolynuclear Gold Complexes Stabilized by a Unique Acetylide Fragment. *Organometallics* **2012**, *31*, 2597–2605.
- (12) (a) Dattelbaum, D. M.; Martin, R. L.; Schoonover, J. R.; Meyer, T. J. Molecular and Electronic Structure in the Metal-to-Ligand Charge Transfer Excited States of *fac*-[Re(4,4'-X₂bpy)(CO)₃(4-Etpy)]⁺ (X = CH₃, H, CO₂Et). Application of density functional theory and time-resolved infrared spectroscopy. *J. Phys. Chem. A* **2004**, *108*, 3518–3526. (b) Gonçalves, M. R.; Frin, K. P. M. Synthesis, characterization, photophysical and electrochemical properties of *fac*-tricarbonyl(4,7-dichloro-1,10-phenanthroline)rhenium(I) complexes. *Polyhedron* **2015**, *97*, 112–117.
- (13) Wallenda, S. V.; Shaver, R. J.; Rillema, D. P.; Yoblinski, B. J.; Stathis, M.; Guarr, T. F. Ground-state and excited-state properties of monometallic and bimetallic complexes based on rhenium(I) tricarbonyl chloride: effect of an insulating vs a conducting bridge. *Inorg. Chem.* **1990**, *29*, 1761–1767.
- (14) Fernández-Moreira, V.; Sastre-Martín, H. Photophysical and bioactivity behavior of *fac*-rhenium(I) derivatives containing ditopic sulfurpyridine ligands. *Inorg. Chim. Acta* **2017**, *460*, 127–133.
- (15) Yamamoto, Y.; Shiotsuka, M.; Onaka, S. Luminescent rhenium(I)–gold(I) hetero organometallics linked by ethynylphenanthrolines. *J. Organomet. Chem.* **2004**, *689*, 2905–2911.
- (16) Kirgan, R. A.; Sullivan, B. P.; Rillema, D. P. Photochemistry and photophysics of coordination compounds: Rhenium. *Top. Current. Chem.* **2007**, *281*, 45–100.
- (17) Pomestchenko, I. E.; Polyansky, D. E.; Castellano, F. N. Influence of a Gold(I)–Acetylide Subunit on the Photophysics of Re(Phen)(CO)₃Cl. *Inorg. Chem.* **2005**, *44*, 3412–3421.
- (18) Yang, L.; Ren, A.-M.; Feng, J.-K.; Liu, X.-D.; Ma, Y.-G.; Zhang, H.-X. Theoretical studies of ground and excited electronic states in a series of rhenium(I) bipyridine complexes containing diarylethynyl-based structure. *Inorg. Chem.* **2004**, *43*, 5961–5972.
- (19) (a) Ortego, L.; Cardoso, F.; Martins, S.; Fillat, M. F.; Laguna, A.; Meireles, M.; Villacampa, M. D.; Gimeno, M. C. Strong inhibition of thioredoxin reductase by highly cytotoxic gold(I) complexes. DNA binding studies. *J. Inorg. Biochem.* **2014**, *130*, 32–37. (b) Gutiérrez, A.; Cativiela, C.; Laguna, A.; Gimeno, M. C. Bioactive gold(I) complexes with 4-mercaptopyrrolidine derivative. *Dalton Trans.* **2016**, *45*, 13483–13490. (c) Fernández-Moreira, V.; Herrera, R. P.; Gimeno, M. C. Anticancer properties of gold complexes with biologically relevant ligands. *Pure Appl. Chem.* **2019**, *91*, 247–270.
- (20) (a) Liu, H.-T.; Xiong, X.-G.; Diem Dau, P.; Wang, Y.-L.; Huang, D.-L.; Li, J.; Wang, L.-S. Probing the nature of gold–carbon bonding in gold–alkynyl complexes. *Nat. Commun.* **2013**, *4*, 2223. (b) Cerrada, E.; Fernández-Moreira, V.; Gimeno, M. C. Gold and platinum alkynyl complexes for biomedical applications. *Adv. Organomet. Chem.* **2019**, *71*, 227–258.
- (21) McKeage, M. J.; Berners-Price, S. J.; Galetti, P.; Bowen, R. J.; Brouwer, W.; Ding, L.; Zhuang, L.; Baguley, B. C. Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. *Cancer Chemother. Pharmacol.* **2000**, *46*, 343–350. (b) Visbal, R.; Fernández-Moreira, V.; Marzo, I.; Laguna, A.; Gimeno, M. C. Cytotoxicity and biodistribution studies of luminescent Au(I) and Ag(I) N-heterocyclic carbenes. Searching for new biological targets. *Dalton Trans.* **2016**, *45*, 15026–15033.
- (22) Clède, S.; Lambert, F.; Saint-Fort, R.; Plamont, M.-A.; Bertrand, H.; Vessièrès, A.; Policar, C. Influence of the Side-Chain Length on the Cellular Uptake and the Cytotoxicity of Rhenium Tricarbonyl Derivatives: A Bimodal Infrared and Luminescence Quantitative Study. *Chem. - Eur. J.* **2014**, *20*, 8714–8722.
- (23) Zalba, S.; ten Hagen, T. L. M. Cell membrane modulation as adjuvant in cancer therapy. *Cancer Treat. Rev.* **2017**, *52*, 48–57.
- (24) Galeotti, T.; Borrello, S.; Minotti, G.; Masotti, L. Membrane alterations in cancer cells: the role of oxy radicals. *Ann. N. Y. Acad. Sci.* **1986**, *488*, 468–480.
- (25) *CysAlisPro*, version 1.171.35.11; Agilent Technologies: Yarnton, United Kingdom.
- (26) Sheldrick, G. M. Crystal structure refinement with *SHELXL*. *Acta Crystallogr., Sect. C: Struct. Chem.* **2015**, *71*, 3–8.
- (27) Gibson, D.; Johnson, B. F. G.; Lewis, J. Metal β-diketone complexes. Part VI. Some β-diketone complexes of copper(I), silver(I), and gold(I). *J. Chem. Soc. A* **1970**, *0*, 367–369.
- (28) McCleverty, J. A.; da Mota, M. M. Isocyanide and carbenecomplexes of gold(I). The stepwise formation of formamides. *J. Chem. Soc., Dalton Trans.* **1973**, 2571–2574.
- (29) McAuliffe, C. A.; Parish, R. V.; Randall, P. D. Gold(I) complexes of unidentate and bidentate phosphorus-, arsenic-, antimony-, and sulphur-donor ligands. *J. Chem. Soc., Dalton Trans.* **1979**, 1730–1735.
- (30) Johnson, A.; Gimeno, M. C. An efficient and sustainable synthesis of NHC gold complexes. *Chem. Commun.* **2016**, *52*, 9664–9667.
- (31) (a) Meier-Menches, S. M.; Casini, A. Design strategies and medicinal applications of metal peptidic-bioconjugates. *Bioconjugate Chem.* **2020**, DOI: 10.1021/acs.bioconjchem.0c00152. (b) Gutierrez,

A.; Gimeno, M. C.; Marzo, I.; Metzler-Nolte, N. Synthesis, Characterization, and Cytotoxic Activity of AuI N,S-Heterocyclic Carbenes Derived from Peptides Containing L-Thiazolylalanine. *Eur. J. Inorg. Chem.* **2014**, 2014, 2512–2519.